Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA to reclassify CO(2) and oxygen monitors:

This article was originally published in Clinica

Executive Summary

The FDA has issued a guidance document on filing a premarket notification application for cutaneous carbon dioxide and oxygen monitors. At the same time, it proposes to reclassify these products in light of the new document. Cutaneous carbon dioxide monitors will be reclassified from class II (need to comply with performance standards) to class II (need to comply with special controls) - the guidance document; and the cutaneous oxygen monitor for an infant patient not under gas anaesthesia is reclassified from class II performance standards into class I special controls, while the cutaneous oxygen monitor for all other uses will be downclassified from the high-risk class II category requiring premarket approval into class II special controls. Comments on the reclassification are due by April 15.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel